New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
07:49 EDTXON, OGENOragenics advancing towards identification of lead antibiotic clinical candidate
Oragenics (OGEN) announced that through its Exclusive Channel Collaboration with Intrexon Corporation (XON), it has produced and analyzed a large number of new potential analogs generated from its Mutacin 1140 antibiotic program platform, and advanced several promising compounds for further evaluation. These compounds will serve as the basis for selecting a lead drug candidate for clinical development later this year. The triaged analogs were selected from hundreds of variants generated using genetic engineering at Intrexon. Dr. John N. Bonfiglio, CEO of Oragenics, remarked, "The compounds we have selected for final evaluation align with our goal of identifying the first lead compound this year. We plan on meeting with the FDA later this year to discuss the IND enabling activities necessary to submit an IND application by mid-2015. Intrexon’s synthetic biology expertise in collaboration with our scientists has enabled generation of a large library of new potential MU1140 analogs with chemical and biological properties that differentiate from native MU1140. We remain very optimistic that these new lantibiotics will become useful in the fight against certain drug-resistant bacteria.”
News For OGEN;XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2015
11:01 EDTXONCitron says 'been waiting' for opportunity to buy Intrexon
Subscribe for More Information
09:11 EDTXONIntrexon 4.7M share Spot Secondary priced at $41.00
Subscribe for More Information
August 20, 2015
19:02 EDTXONOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTXONIntrexon to offer common stock, no amount given
JMP Securities is acting as sole book-running manager and Stifel is acting as lead manager for the offering.
08:03 EDTXONIntrexon and Dominion enter exclusive agreement in Marcellus and Utica basins
Intrexon (XON) announced that Intrexon Energy Partners, and Dominion Energy, a subsidiary of Dominion (D), have entered into an agreement to explore the potential for commercial-scale biological conversion of natural gas to isobutanol, a drop-in fuel with numerous advantages over other clean burning gasoline blendstocks. Under the terms of the agreement, IEP will be required to meet specific development milestones prior to initiation of certain commercialization activities, which are subject to board approval by both parties. Dominion will be the exclusive partner to construct, own, operate, and maintain the production facilities in the Marcellus and Utica Shale Basins located in eastern North America via potential long-term services agreements with IEP. Within this geographic region, the collaboration plans to build natural gas bioconversion facilities leading to the creation of job opportunities and generation of local and state tax revenue.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use